

Diagnostik von angeborenen und erworbenen Thrombozyten-Erkrankungen

1. O'Brien SH. An update on pediatric bleeding disorders: bleeding scores, benign joint hypermobility, and platelet function testing in the evaluation of the child with bleeding symptoms. *American journal of hematology*. 2012 May;87 Suppl 1:S40-4. PubMed PMID: 22460356.
2. Dovlatova N. Current status and future prospects for platelet function testing in the diagnosis of inherited bleeding disorders. *British journal of haematology*. 2015 Jul;170(2):150-61. PubMed PMID: 25920378.
3. Gross L, Aradi D, Sibbing D. Platelet Function Testing in Patients on Antiplatelet Medications. *Seminars in thrombosis and hemostasis*. 2016 Feb 17. PubMed PMID: 26886395.
4. Andres O, Schulze H, Speer CP. Platelets in neonates: central mediators in haemostasis, antimicrobial defence and inflammation. *Thrombosis and haemostasis*. 2015 Jan;113(1):3-12. PubMed PMID: 25185520.
5. Favalaro EJ, Lippi G, Franchini M. Contemporary platelet function testing. *Clinical chemistry and laboratory medicine*. 2010 May;48(5):579-98. PubMed PMID: 20148722.
6. Knofler R, Eberl W, Schulze H, Bakchoul T, Bergmann F, Gehrisch S, et al. [Diagnosis of inherited diseases of platelet function. Interdisciplinary S2K guideline of the Permanent Paediatric Committee of the Society of Thrombosis and Haemostasis Research (GTH e. V)]. *Hamostaseologie*. 2014;34(3):201-12. PubMed PMID: 24903476. Diagnose angeborener Störungen der Thrombozytenfunktion. Interdisziplinäre S2K-Leitlinie der Ständigen Kommission Pädiatrie der Gesellschaft für Thrombose- und Hamostaseforschung e. V.
7. Jansen AJ, Josefsson EC, Rumjantseva V, Liu QP, Falet H, Bergmeier W, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIIb/IIIa metalloproteinase-mediated cleavage in mice. *Blood*. 2012 Feb 2;119(5):1263-73. PubMed PMID: 22101895. Pubmed Central PMCID: 3277358.
8. Hoffmeister KM. The role of lectins and glycans in platelet clearance. *Journal of thrombosis and haemostasis : JTH*. 2011 Jul;9 Suppl 1:35-43. PubMed PMID: 21781240. Pubmed Central PMCID: 4303235.
9. Schneppenheim R. The pathophysiology of von Willebrand disease: therapeutic implications. *Thrombosis research*. 2011;128 Suppl 1:S3-7. PubMed PMID: 22221847.
10. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program*. 2013;2013:254-60. PubMed PMID: 24319188.
11. Marcus PD, Nire KG, Grooms L, Klima J, O'Brien SH. The power of a standardized bleeding score in diagnosing paediatric type 1 von Willebrand's disease and platelet function defects. *Haemophilia : the official journal of the World Federation of Hemophilia*. 2011 Mar;17(2):223-7. PubMed PMID: 20860605.
12. Robinson PN, Kohler S, Bauer S, Seelow D, Horn D, Mundlos S. The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. *American journal of human genetics*. 2008 Nov;83(5):610-5. PubMed PMID: 18950739. Pubmed Central PMCID: 2668030.
13. Westbury SK, Turro E, Greene D, Lentaigne C, Kelly AM, Bariana TK, et al. Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. *Genome medicine*. 2015;7(1):36. PubMed PMID: 25949529. Pubmed Central PMCID: 4422517.
14. Briggs C, Harrison P, Machin SJ. Continuing developments with the automated platelet count. *International journal of laboratory hematology*. 2007 Apr;29(2):77-91. PubMed PMID: 17474881.
15. Nurden AT, Nurden P. Congenital platelet disorders and understanding of platelet function. *British journal of haematology*. 2014 Apr;165(2):165-78. PubMed PMID: 24286193.
16. Quiroga T, Goycoolea M, Panes O, Aranda E, Martinez C, Belmont S, et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. *Haematologica*. 2007 Mar;92(3):357-65. PubMed PMID: 17339185.
17. Pecci A, Noris P, Invernizzi R, Savoia A, Seri M, Ghiggeri GM, et al. Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders. *British journal of haematology*. 2002 Apr;117(1):164-7. PubMed PMID: 11918549.
18. Navarro-Nunez L, Teruel R, Anton AI, Nurden P, Martinez-Martinez I, Lozano ML, et al. Rare homozygous status of P43 beta1-tubulin polymorphism causes alterations in platelet ultrastructure. *Thrombosis and haemostasis*. 2011 May;105(5):855-63. PubMed PMID: 21384078.
19. Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, et al. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. *Journal of thrombosis and haemostasis : JTH*. 2013 Apr 10. PubMed PMID: 23574625.

20. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. *Seminars in thrombosis and hemostasis*. 2009 Mar;35(2):168-80. PubMed PMID: 19408190.
21. Peerschke EI, Castellone DD, Stroobants AK, Francis J. Reference range determination for whole-blood platelet aggregation using the Multiplate analyzer. *Am J Clin Pathol*. 2014 Nov;142(5):647-56. PubMed PMID: 25319980.
22. Pai M, Wang G, Moffat KA, Liu Y, Seecharan J, Weibert K, et al. Diagnostic usefulness of a lumi-aggregometer adenosine triphosphate release assay for the assessment of platelet function disorders. *Am J Clin Pathol*. 2011 Sep;136(3):350-8. PubMed PMID: 21846909.
23. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. *Seminars in thrombosis and hemostasis*. 2009 Mar;35(2):158-67. PubMed PMID: 19408189.
24. Cattaneo M, Hayward CP, Moffat KA, Pugliano MT, Liu Y, Michelson AD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. *Journal of thrombosis and haemostasis : JTH*. 2009 Jun;7(6):1029. PubMed PMID: 19422455.
25. Israels SJ, Kahr WH, Blanchette VS, Luban NL, Rivard GE, Rand ML. Platelet disorders in children: A diagnostic approach. *Pediatric blood & cancer*. 2011 Jun;56(6):975-83. PubMed PMID: 21294245.
26. Gresele P, Subcommittee on Platelet Physiology of the International Society on T, Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. *Journal of thrombosis and haemostasis : JTH*. 2015 Feb;13(2):314-22. PubMed PMID: 25403439.
27. Bakchoul T, Zollner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. *International journal of laboratory hematology*. 2014 Jun;36(3):296-305. PubMed PMID: 24750676.
28. Margaret Prechel AMHaJMW. Cross Reactivity of Heparin-Induced PF4 Antibodies with Heparin-Bound IL-8. *Blood*. 2008 2008;112(11).
29. Althaus K, Hron G, Strobel U, Abbate R, Rogolino A, Davidson S, et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. *Thromb Res*. 2013 3/2013;131(3):e85-e90.
30. Arepally G, Reynolds C, Tomaski A, Amiral J, Jawad A, Poncz M, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. *American journal of clinical pathology*. 1995 Dec;104(6):648-54. PubMed PMID: 8526207. Epub 1995/12/01. eng.
31. Bakchoul T, Giptner A, Bein G, Santoso S, Sachs UJ. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). *Thromb Res*. 2011 Apr;127(4):345-8. PubMed PMID: 21232785. Epub 2011/01/15. eng.
32. Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. *J Thromb Haemost*. 2009 Aug;7(8):1260-5. PubMed PMID: 19422442. Epub 2009/05/09. eng.
33. Lindhoff-Last E, Gerdson F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. *Br J Haematol*. 2001 Jun;113(4):886-90. PubMed PMID: 11442479.
34. Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Regina S, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. *J Thromb Haemost*. 2007 Jul;5(7):1373-9. PubMed PMID: 17362241.
35. Sachs UJ, von HJ, Santoso S, Bein G, Bakchoul T. Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). *Thromb Haemost*. 2011 12/2011;106(6):1197-202.
36. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. *Blood*. 2010 Sep 9;116(10):1761-6. PubMed PMID: 20508160. Pubmed Central PMCID: 2947396. Epub 2010/05/29. eng.
37. Whitlatch NL, Perry SL, Ortel TL. Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. *Thromb Haemost*. 2008 Oct;100(4):678-84. PubMed PMID: 18841292.
38. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. *Thromb Haemost*. 1991 Dec 2;66(6):734-6. PubMed PMID: 1796420.
39. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. *Blood*. 1986 Jan;67(1):27-30. PubMed PMID: 3940551.
40. Consortium UK, Walter K, Min JL, Huang J, Crooks L, Memari Y, et al. The UK10K project identifies rare variants in health and disease. *Nature*. 2015 Oct 1;526(7571):82-90. PubMed PMID: 26367797.

41. Gieger C, Radhakrishnan A, Cvejic A, Tang W, Porcu E, Pistis G, et al. New gene functions in megakaryopoiesis and platelet formation. *Nature*. 2011 Dec 8;480(7376):201-8. PubMed PMID: 22139419. Pubmed Central PMCID: 3335296.
42. Noris P, Perrotta S, Seri M, Pecci A, Gnan C, Loffredo G, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. *Blood*. 2011 Jun 16;117(24):6673-80. PubMed PMID: 21467542.
43. Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. *Nature genetics*. 2015 May;47(5):535-8. PubMed PMID: 25807284. Pubmed Central PMCID: 4631613.
44. Jongmans MC, Kuiper RP, Carmichael CL, Wilkins EJ, Dors N, Carmagnac A, et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. *Leukemia*. 2010 Jan;24(1):242-6. PubMed PMID: 19946261.
45. Buitrago L, Rendon A, Liang Y, Simeoni I, Negri A, ThromboGenomics C, et al. alphasbeta3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia. *Proceedings of the National Academy of Sciences of the United States of America*. 2015 Apr 14;112(15):E1898-907. PubMed PMID: 25827233. Pubmed Central PMCID: 4403182.

Therapeutische Hämapherese

1. Blum W, Porcu P. Therapeutic Apheresis in Hyperleukocytosis and Hyperviscosity Syndrome. *Semin Thromb Hemost* 2007;33:350-4.
2. Hölig K, Moog R. Leukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia. *Transfusion Medicine and Hemotherapy* 2012;39:241-5.
3. Novotny JR, Müller-Beißenhirtz H, Herget-Rosenthal S, Kribben A, Dührsen U. Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. *European Journal of Haematology* 2005;74:501-10.
4. Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival. *Leukemia & Lymphoma* 2001;42:67-73.
5. Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. *Transfusion* 2007;47:1843-50.
6. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. *Journal of Clinical Apheresis* 2016;31:149-338.
7. Spaete J, Patrozou E, Rich JD, Sweeney JD. Red cell exchange transfusion for babesiosis in Rhode Island. *Journal of Clinical Apheresis* 2009;24:97-105.
8. Van Genderen PJJ, Hesselink DA, Bezemer JM, Wismans PJ, Overbosch D. Efficacy and safety of exchange transfusion as an adjunct therapy for severe *Plasmodium falciparum* malaria in nonimmune travelers: a 10-year single-center experience with a standardized treatment protocol. *Transfusion* 2010;50:787-94.
9. Schafer AI. Thrombocytosis. *New England Journal of Medicine* 2004;350:1211-9.
10. Rock GA. Management Of Thrombotic Thrombocytopenic Purpura. *British Journal of Haematology* 2000;109:496-507.
11. Fontana S, Kremer Hovinga JA, Lämmle B, Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. *Vox Sanguinis* 2006;90:245-54.
12. Bambauer R, Schiel R, Latza R. Low-density Lipoprotein Apheresis: An Overview. *Therapeutic Apheresis and Dialysis* 2003;7:382-90.

Periinterventionelles Management direkter oraler Antikoagulanzen (DOAKs)

1. Harbrecht, U., Old and new anticoagulants. *Hamostaseologie*, 2011. 31(1): p. 21-7.
2. Douketis, J.D., et al., The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, 2008. 133(6 Suppl): p. 299-339.
3. Eisele, R., N. Melzer, and P. Bramlage, Perioperative management of anticoagulation. *Chirurg*, 2014. 85(6): p. 513-9.
4. Giebl, A. and K. Gurtler, New oral anticoagulants in perioperative medicine. *Anaesthesist*, 2014. 63(4): p. 347-62.
5. Lee, L.H., DOACs - advances and limitations in real world. *Thrombosis Journal*, 2016. 14(Suppl 1): p. 134-163.
6. van Es, N., et al., Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. *Blood*, 2014. 124(12): p. 1968-75.
7. Tummala, R., et al., Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. *Int J Cardiol*, 2016. 214: p. 292-8.
8. Siegal, D.M. and M.A. Crowther, Acute management of bleeding in patients on novel oral anticoagulants. *Eur Heart J*, 2013. 34(7): p. 489-498b.
9. Waurick, K., et al., 3. überarbeitete Empfehlung der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin: S1-Leitlinie „Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/antithrombotische Medikation“. *Anästhesiologie & Intensivmedizin*, 2014. 55: p. 464-492.
10. Hart, C. and M. Spannagl, Gerinnungsmonitoring der direkten oralen Antikoagulanzen. *Kardiologie up2date*, 2013. 9: p. 197-211.
11. Samos, M., et al., Monitoring of dabigatran therapy using Hemoclot((R)) Thrombin Inhibitor assay in patients with atrial fibrillation. *J Thromb Thrombolysis*, 2015. 39(1): p. 95-100.
12. Grottke, O. and J.H. Levy, Prothrombin complex concentrates in trauma and perioperative bleeding. *Anesthesiology*, 2015. 122(4): p. 923-31.
13. Siegal, D.M. and A. Cuker, Reversal of novel oral anticoagulants in patients with major bleeding. *J Thromb Thrombolysis*, 2013. 35(3): p. 391-8.
14. Finks, S.W. and K.C. Rogers, Idarucizumab (Praxbind(R)): The first reversal agent for a direct oral anticoagulant. *The American Journal of Medicine*, 2016.

Zur Anwender-Reklamation „Koagel in Erythrozytenkonzentraten“

1. Thomas L. (Hrsg.). Labor und Diagnose. 8. Auflage 2012, TH-Books Verlagsgesellschaft Frankfurt.
2. Kiefel V. (Hrsg.). Transfusionsmedizin und Immunhämatologie, 4. Auflage 2010, Springer-Verlag Berlin Heidelberg.
3. Huestis DW, Bove JR, Case J. Practical Blood Transfusion. 4. Auflage 1988, Little, Brown and Company Boston / Toronto
4. Petrides M, Stack, G. Practical Guide to Transfusion Medicine. 2001, AABB Press Bethesda Maryland.
5. McCullough J. Transfusion Medicine. 1998, McGraw-Hill Health Professional Division. New York
6. Ryden SE, Obermann HA. Compatibility of Common Intravenous Solutions with CPD Blood. Transfusion 1975; 15 : 250 – 255.
7. Wagner T et al., Der Anaesthesist, 2008, S. 1167 – 1171, Blutkoagel in Erythrozytenkonzentraten während der Transfusion

Inkompatibles Universal-Erythrozytenkonzentrat bei seltener Rhesus-Inkompatibilität zwischen Mutter und Kind

1. Zimmermann, B.: Transfusionsmedizinische Versorgung von Früh- und Neugeborenen. Hämotherapie, 2011, 17, 40-53
2. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) Gesamtnovelle 2005 mit Richtlinienanpassung 2010 Deutscher Ärzteverlag Köln
3. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 4. überarbeitete Auflage 2009 , 2009, Deutscher Ärzte-Verlag
4. Mollison P L, Engelfriet C P, Contreras M. Blood transfusion in clinical medicine.; Blackwell 1997
5. Singla S, Kumar S, Kumar RK, Sharma JB, Kachhawa G (2010) Severe hydrops in the infant of a Rhesus D positive mother due to anti-c antibodies diagnosed antenatally: a case report. J Case Rep 4:57
6. Koelewijn, J.M., Vrijkotte, T.G.M., Van Der Schoot, C.E., Bonsel, G.J. and De Haas, M. (2008), Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion, 48: 941–952.
7. Sheeladevi CS, Suchitha S, Manjunath GV, Murthy S. Hemolytic Disease of the Newborn Due to Anti-c Isoimmunization: A Case Report. Indian Journal of Hematology & Blood Transfusion. 2013;29(3):155-157.
8. Leger, RM. Positive DAT and immune-mediated hemolysis. In: Roback JD (ed). Technical manual. 17th ed. Bethesda, MD: American Association of Blood Banks, 2011:505–6.
9. Heddle N M, Wentworth P, Anderson D R, Emmerson D, Kelton J G, Blajchman M A. Three examples of Rh haemolytic disease of the newborn with a negative direct antiglobulin test. Transfusion Medicine. 1995; 5 113-11
10. Garratty G, Telen MJ, Petz LD. Red cell antigens as functional molecules and obstacles to transfusion. Hematology AmSoc Hematol Educ Program 2002:445–50.
11. Eckstein R., Zimmermann R. Immunhämatologie und Klinische Transfusionsmedizin: Theorie und Praxis Kompakt. Elsevier GmbH, 6. Auflage, 2010
12. Heddle N M, Wentworth P, Anderson D R, Emmerson D, Kelton J G, Blajchman M A. Three examples of Rh haemolytic disease of the newborn with a negative direct antiglobulin test. Transfusion Medicine. 1995; 5 113-11
13. Merry AH, Thomson EE, Rawlinson VI, et al. Quantitation of IgG on erythrocytes: correlation of number of IgG molecules per cell with the strength of the direct and indirect antiglobulin tests. Vox Sang 1984;47:73–81.